Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes (ACR Convergence 2025) - Sep 15, 2025 - Abstract #1544; Pres time: Oct 27, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "Standard therapies—high-dose corticosteroids combined with mycophenolate mofetil or cyclophosphamide—achieve complete renal remission in a limited subset of patients and carry substantial toxicity. Voclosporin significantly improves CRR at 6 months and 1 year in patients with LN, with an overall safety profile comparable to placebo. However, gastrointestinal and neurological adverse events were more common. Further studies are needed to assess long-term outcomes, define steroid-sparing protocols, optimize dosing, and evaluate efficacy across diverse populations to determine voclosporin's definitive role in LN treatment."
Retrospective data • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Sri Laxmi Priya Sunkara1; Ravi Medarametla2; Megha Kotha3; Wael Jarjour4
|